S&P Futures
4,030.50 +29.00 (+0.72%) Dow Futures
32,750.00 +162.00 (+0.50%) Nasdaq Futures
12,828.00 +95.50 (+0.75%) Russell 2000 Futures
1,780.90 +16.10 (+0.91%) Crude Oil
73.71 +0.51 (+0.70%) Gold
1,961.70 -11.80 (-0.60%)
ALZAMEND NEURO INC -,0001 (9ZT0.HM)
Chart Events
Performance Outlook
| Previous Close | 0.4115 |
| Open | 0.3993 |
| Bid | 0.3989 x N/A |
| Ask | 0.4089 x N/A |
| Day's Range | 0.3993 - 0.3993 |
| 52 Week Range | 0.3642 - 1.4780 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
Alzamend Neuro Inc (NASDAQ: ALZN) announced it had completed the clinical portion of its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer’s. This blinded, placebo-controlled trial (AL001-02) was initiated in May 2022 and is designed to evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose in patients diagnosed with mild to moderate Alzheimer’s and healthy subjects. Al
- Business Wire
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA, March 22, 2023--Alzamend Neuro Completes Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
- Simply Wall St.
We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
